One-third of adults across the globe exhibit metabolic dysfunction-associated steatotic liver disease (MASLD)―formerly known as nonalcoholic fatty liver disease (NAFLD). To date, MASLD is the fastest-growing etiology of chronic liver disease and hepatocellular carcinoma (HCC). Besides the population with obesity, MASLD can also be found in lean populations, accounting for 13% of the global population, especially Asians. Notably, individuals with lean MASLD face equal or higher overall mortality rates compared to their non-lean counterparts. Risk modifiers encompass advanced age, hepatic fibrosis, and type 2 diabetes mellitus (T2DM). Moreover, the population with lean MASLD is associated with an increased risk of HCC, while their non-lean counterparts are more prone to cardiovascular outcomes and T2DM. Existing evidence indicates a similar risk of liver-related events and extrahepatic cancer between the two groups. However, MASLD-related genetic variants, such as PNPLA3 and TM6SF2, did not significantly affect mortality between the two populations. Still, underreporting alcohol consumption and regional representation limits the study’s comprehensiveness. Longitudinal studies and mechanistic explorations are needed to understand differences in lean versus non-lean MASLD populations. This review highlights the need for awareness and tailored interventions in managing MASLD, considering lean individuals’ unique risks.
Citations
Citations to this article as recorded by
Dietary vitamin E intake in metabolic dysfunction–associated steatotic liver disease and all-cause/cause-specific mortality Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Aijaz Ahmed European Journal of Gastroenterology & Hepatology.2026; 38(1): 63. CrossRef
Social Determinants of Health in Metabolic Dysfunction‐Associated Steatotic Liver Disease and All‐Cause/Cause‐Specific Mortality Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Rohit Loomba, Aijaz Ahmed Alimentary Pharmacology & Therapeutics.2026; 63(5): 662. CrossRef
The Influence of Metabolic Dysfunction-Associated Steatotic Liver Disease and Body Mass Index on the Incidence of Alzheimer Disease: A Nationwide Cohort Study Tae Seop Lim, Seok Jong Chung, Jimin Jeon, Ja Kyung Kim, Jinkwon Kim Gut and Liver.2026; 20(1): 107. CrossRef
Contemporary trends in extrahepatic mortality of chronic liver disease in the United States from 2014 to 2023 Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Aijaz Ahmed Clinical and Molecular Hepatology.2026; 32(1): e24. CrossRef
Association of Metabolic Dysfunction–Associated Steatotic Liver Disease With Features of Cerebral Small‐Vessel Disease on Magnetic Resonance Images: A Large Cross‐Sectional Study Yaqin Wang, Kui Chen, Changfa Wang, Zhongyang Hu, Xiaoling Zhu, Lei Liu Journal of the American Heart Association.2026;[Epub] CrossRef
Epigenetic Aging Biomarkers in Lean MAFLD Ziyan Pan, Shadi Zerehpoosh, Mohammed Eslam Liver International.2026;[Epub] CrossRef
Challenges in defining MASLD in lean individuals: the impact of the Fatty Liver Index on phenotypic characterisation Sherlot Juan Song, Yiwei Liu, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip Gut.2026; : gutjnl-2026-338216. CrossRef
Providing holistic care for patients with metabolic dysfunction‐associated steatotic liver disease/metabolic dysfunction‐associated steatohepatitis: Key aspects of clinical assessment and how to develop individualised care plans for surveillance and inter Lanlan Chen, Paul Horn, Frank Tacke Diabetes, Obesity and Metabolism.2026; 28(S2): 46. CrossRef
Disparities in Liver Transplantation Among Native Americans and Hispanic Individuals: Insights from a Southwest Region Center in the United States of America Anandalakshmi Ponnaluri, Pooja Rangan, Pojsakorn Danpanichkul, Andrew Bell, Rebecca Postagate, Moises Ilan Nevah Rubin, Michael B. Fallon, Karn Wijarnpreecha Journal of Clinical Medicine.2026; 15(3): 953. CrossRef
Human milk fat substitutes improve obesity-related NAFLD by enriching LPC 18:2 to activate hepatic GPR119–AMPK signaling Yangzheng He, Jing Li, Zhigang Wen, Yong Sun, Liufeng Zheng, Hongyan Li, Zeyuan Deng Journal of Advanced Research.2026;[Epub] CrossRef
Revisiting the Obesity Paradox in Metabolic Dysfunction-associated Steatotic Liver Disease: Longitudinal Trajectory Analysis Reveals Time-varying Mortality Risks Zhen Sun, Jinhao Li, Xuefei Yu, Yuchen Jiang, Jiaojiao Zheng, Yuan Ouyang, Ming Guan, Xuan Deng, Bo Li, Haojie Jin Clinical Gastroenterology and Hepatology.2026;[Epub] CrossRef
Increased Cardiovascular and Cerebrovascular Events in Patients With Lean vs Non-lean MASLD: A Multicenter Analysis Omar Al Ta'ani, Yahya Alhalalmeh, Mohammad Alabdallat, Abdallah Naser, Saqr Alsakarneh, Saleh Saleh, Pojsakorn Danpanichkul, Dushyant Dahiya Singh, Basile Njei, Nikki Duong Clinical and Translational Gastroenterology.2026; 17(4): e00974. CrossRef
Impact of Documented Social Vulnerability on Clinical Outcomes in Metabolic Dysfunction‐Associated Steatotic Liver Disease Pojsakorn Danpanichkul, Yanfang Pang, Maria Inggriani, Supapitch Sirimangklanurak, Matheus Souza, Ahmad Anouti, Andrew F. Ibrahim, Nikki Duong, Thomas G. Cotter, Thomas A. Kerr, Donghee Kim, Mazen Noureddin, Karn Wijarnpreecha Liver International.2026;[Epub] CrossRef
Liver, Cardiovascular and Infectious Outcomes in Alcohol‐Associated Liver Disease With Cardiometabolic Risk Factors Pojsakorn Danpanichkul, Kwanjit Duangsonk, Yanfang Pang, Krittameth Rakwong, Peerapun Jit‐are‐roon, Phuuwadith Wattanachayakul, Thitiphan Srikulmontri, Benjamin Nah, Vincent L. Chen, Donghee Kim, Christos S. Mantzoros, Mazen Noureddin, Karn Wijarnpreecha Liver International.2026;[Epub] CrossRef
Normal-weight metabolic dysfunction-associated steatotic liver disease: reclassification, characteristics, and adverse liver outcomes across diverse populations Sherlot Juan Song, Eileen Laureal Yoon, Vincent Wai-Sun Wong, Ae Jeong Jo, Grace Lai-Hung Wong, Jimmy Che-To Lai, Dae Won Jun, Terry Cheuk-Fung Yip Clinical and Molecular Hepatology.2026; 32(2): 646. CrossRef
Body Roundness Index and All‐Cause Mortality in Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Dual‐Cohort Study Zijian Li, Shishu Yin, Jian Cui, Jinxin Shi, Fuhai Ma, Tianming Ma, Qi An, Tao Yu, Danian Tang, Xianglong Cao, Gang Zhao Diabetes, Obesity and Metabolism.2026; 28(6): 4961. CrossRef
Central obesity measured by weight-adjusted waist index is associated with lean MASLD Ziteng Wang, Wentao Tan, Zhe Yu, Herui Wei, Jing Luo, Wen An, Mengqi Li, Qi Gao, Lijuan Sun, Aqian Song, Lingling He, Jiali Ma, Fan Xiao, Hong Liu, Hui Zhong, Hongshan Wei Clinics and Research in Hepatology and Gastroenterology.2026; 50(5): 102822. CrossRef
Burden and Health System Challenges in MASLD Across East and Southeast Asia: A Narrative Review Jonathan Jaime G. Guerrero, Paolo C. Encarnacion, Wan‐Yu Wang, Shu‐Fen Liao, Ching‐Wen Chang Health Science Reports.2026;[Epub] CrossRef
Integrated bioinformatics analysis and experimental validation of SRF as a potential senescence biomarker in MASLD Mengyue Li, Chang Gao, Yuhui Shi, Wenyu Peng, Yuan Yin, Bin Lu, Zhang Fu Frontiers in Molecular Biosciences.2026;[Epub] CrossRef
Multicenter Prospective Cohort Study on Clinical Outcomes and Fibrosis Patterns in Biopsy-Proven Steatotic Liver Disease Subtypes Gi-Ae Kim, Heejoon Jang, Moon Young Kim, Jeong Hwan Park, Jung Gil Park, Eun-Young Cho, Jae Yoon Jeong, Seogsong Jeong, Seul Ki Han, Heesu Kwon, Youngae Jung, Geum-Sook Hwang, Yu Rim Lee, Soo Young Park, Sang Gyune Kim, Won Kim Gastroenterology.2026; 170(7): 1571. CrossRef
Outcomes of liver and cardiovascular metabolic diseases among lean vs non-lean individuals with metabolic dysfunction-associated steatotic liver disease Mexan Mapouka, Evariste Pabingui, Nkengeh N Tazinkeng, Milkessa Gurmessa, Ulrich Vickos, Nkafu Bechem Ndemazie, Serge Magloire Camengo Police World Journal of Gastroenterology.2026;[Epub] CrossRef
Arachidonoyl-taurine is elevated in human MASLD and protects against hepatic steatosis and inflammation in preclinical models Katharina B. Kuentzel, Samuel A.J. Trammell, Anna S. Hassing, Ivan Bradić, Michelle Damgaard, Emma B. Fals, Katja T. Michler, Matthew Dooley, Jens C.B. Jacobsen, Malte P. Suppli, Mikkel P. Werge, Cameron J. Mitchell, Nicolai J. Wewer Albrechtsen, Lise L. Journal of Hepatology.2026;[Epub] CrossRef
Predictive value of TyG-BMI, CTI, and SII in identifying metabolic dysfunction-associated steatotic liver disease among patients with type 2 diabetes mellitus Yue Chen, Yayu Lai, Qu Xiang, Li Fan, Xingyu Chen, Jin Gao, Qingfeng Cheng, Xu Luo Frontiers in Nutrition.2026;[Epub] CrossRef
Metabolic Dysfunction-Associated Steatotic Liver Disease and Incretin Receptor Agonists: A Metabolic Approach to Halting Liver Disease Progression Ludovico Abenavoli, Anna Giulia Loricchio, Ivo Lopez, Domenico Morano, Abdulrahman Ismaiel, Dan Lucian Dumitrascu, Francesco Luzza Medicina.2026; 62(5): 986. CrossRef
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Clinical Profile, Phenotypes, and Risk Stratification. A Narrative Review Zalina Yuryevna Sozaeva, Marina Vsevolodovna Atayeva, Elizaveta Olegovna Salatova, Irina Kazbekovna Alikova, Alexandra Evgenievna Dolgaya, Amin Gasaevich Magomedov, Kamilla Ramisovna Hafsi, Nur-Mukhamed Aslanovich Shomakhov, Elena Mukhadinovna Pshukova, Y Journal of Biochemical Technology.2026; 17(2): 30. CrossRef
MASLD prevalence, incidence and global aspects Sarah H. Wild, Jeffrey V. Lazarus, C. Wendy Spearman, Ponsiano Ocama, Josh Bilson, Xiao-Dong Zhou, Ming-Hua Zheng, Christopher D. Byrne Diabetologia.2026;[Epub] CrossRef
Predictors of Discordance Between Controlled Attenuation Parameter and Magnetic Resonance-Proton Density Fat Fraction in Hepatic Steatosis Dong Yun Kim, Hyung-Jin Rhee, Beom Kyung Kim Clinical and Translational Gastroenterology.2026; 17(7): e01042. CrossRef
Contemporary epidemiology of metabolic dysfunction-associated steatotic liver disease Do Han Kim, Donghyun Ko, Aijaz Ahmed, Donghee Kim Expert Review of Gastroenterology & Hepatology.2026; 20(6): 603. CrossRef
Metabolic Dysfunction‐Associated Fatty Liver Disease: From Pathogenesis to Treatment Zhifu Cui, Xiaxia Du, Felix Kwame Amevor, Yaoyao Xia, You Yang, Lingbin Liu MedComm.2026;[Epub] CrossRef
Review of Obesity and Cancer Zi-Li Huang, Wen-Tao Song, Xiu-Yan Huang JAMA.2026;[Epub] CrossRef
Cryptogenic steatotic liver disease: a lean phenotype associated with increased liver-related mortality Eileen Laurel Yoon, Hyo Young Lee, Jonghyun Lee, Joo Hyun Oh, Inseok Hwang, Chan Hee Park, Sejung Kim, Huiyul Park, Ae Jeong Jo, Dae Won Jun Gut.2026; : gutjnl-2026-339142. CrossRef
Uric Acid-to-HDL Cholesterol Ratio is Associated with Hepatic Steatosis but Not Fibrosis in Nonobese Adults: A NHANES 2017–2020 Study Linwan Li, Xiang’an Zhao Metabolic Syndrome and Related Disorders.2026;[Epub] CrossRef
Metabolic dysfunction–associated steatotic liver disease (MASLD) is under-recognised: Should hepatic elastography be integrated into early risk stratification for people with type 2 diabetes? Aftab Ala, Ponnusamy Saravanan Clinical Medicine.2026; : 100629. CrossRef
Phthalates exposure, biological aging, and increased risks of insulin resistance, prediabetes, and diabetes in adults with metabolic dysfunction-associated steatotic liver disease Yueru Yang, Shuhui Wan, Linling Yu, Wei Liu, Jiahao Song, Da Shi, Yongfang Zhang, Weihong Chen, Weihong Qiu, Bin Wang Diabetes & Metabolism.2025; 51(1): 101602. CrossRef
Increased MASH-associated liver cancer in younger demographics Pojsakorn Danpanichkul, Yanfang Pang, Kanokphong Suparan, Thanida Auttapracha, Supapitch Sirimangklanurak, Abdelrahman M. Attia, Chanattha Thimphitthaya, Michelle Shi Ni Law, Zhenning Yu, Mostafa A. Soliman, Natchaya Polpichai, Chanakarn Kanitthamniyom, D Hepatology Communications.2025;[Epub] CrossRef
Alcohol–Related Liver Disease, Followed by Metabolic Dysfunction–Associated Steatotic Liver Disease, Emerges as the Fastest‐Growing Aetiologies for Primary Liver Cancer in the United States Pojsakorn Danpanichkul, Kwanjit Duangsonk, Markos Kalligeros, Michael B. Fallon, Chawinthorn Vuthithammee, Chun Wei Pan, Preenapun Saokhieo, William Derrick, Yanfang Pang, Vincent L. Chen, Donghee Kim, Amit G. Singal, Ju Dong Yang, Karn Wijarnpreecha Alimentary Pharmacology & Therapeutics.2025; 61(6): 959. CrossRef
Current Burden of Lean Metabolic Dysfunction‐Associated Steatotic Liver Disease Among US Adults, 2017–2023 Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed Alimentary Pharmacology & Therapeutics.2025; 61(5): 891. CrossRef
Comparative application of MAFLD and MASLD diagnostic criteria on NAFLD patients: insights from a single-center cohort Maha Elsabaawy, Madiha Naguib, Ahmed Abuamer, Ahmed Shaban Clinical and Experimental Medicine.2025;[Epub] CrossRef
Advanced lung cancer inflammation index: a key predictor of hepatic steatosis and fibrosis severity Yajie Liu, Ruilin Wang BMC Gastroenterology.2025;[Epub] CrossRef
Association of High‐Sensitivity Troponins in Metabolic Dysfunction‐Associated Steatotic Liver Disease With All‐Cause and Cause‐Specific Mortality Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed Alimentary Pharmacology & Therapeutics.2025; 61(11): 1785. CrossRef
Addressing the burden of steatotic liver disease: The role of transient elastography: Correspondence to editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023” Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed Clinical and Molecular Hepatology.2025; 31(2): e180. CrossRef
Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023 Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed Clinical and Molecular Hepatology.2025; 31(2): 382. CrossRef
Liver cirrhosis in metabolic dysfunction-associated steatohepatitis Donghyun Ko, Do Han Kim, Pojsakorn Danpanichkul, Masahito Nakano, Chitchai Rattananukrom, Karn Wijarnpreecha, Cheng Han Ng, Mark D Muthiah Gastroenterology Report.2025;[Epub] CrossRef
Advances in identifying risk factors of metabolic dysfunction-associated alcohol-related liver disease Rui-Qi Ye, Yi-Fan Chen, Chang Ma, Xi Cheng, Wei Guo, Sha Li Biomedicine & Pharmacotherapy.2025; 188: 118191. CrossRef
Increased Mortality Among Lean Versus Non‐Lean Adults With MASLD: A Multicenter Study Leith Ghani, Majd B. Aboona, Claire S. Faulkner, Pooja Rangan, Moises Nevah Rubin, Ma Ai Thanda Han, Michael B. Fallon, Vincent L. Chen, Karn Wijarnpreecha Journal of Gastroenterology and Hepatology.2025; 40(8): 1919. CrossRef
Evolving Public Attention to Steatotic Liver Disease: A 20‐Year Analysis (2004–2024) Pojsakorn Danpanichkul, Charat Thongprayoon, Kanokphong Suparan, Donghee Kim, Ornpailin Wanichthanaolan, Phuuwadith Wattanachayakul, Yanfang Pang, Mark D. Muthiah, Anand V. Kulkarni, Ju Dong Yang, Apichat Kaewdech, Wisit Cheungpasitporn, Karn Wijarnpreech Journal of Gastroenterology and Hepatology.2025; 40(8): 2053. CrossRef
Meta‐Analysis: Effects of Steatotic Liver Disease‐Associated Genetic Risk Alleles on Longitudinal Outcomes Matthew Kubina, Vitchapong Prasitsumrit, Jarell Tan, Joo Wei Ethan Quek, Dhiraj Peddu, Ankit Mishra, Pojsakorn Danpanichkul, Jake P. Mann, Eric Trépo, Stephan Buch, Daniel Q. Huang, Cheng Han Ng, Mark D. Muthiah, Yu Jun Wong, Karn Wijarnpreecha, Vincent L Alimentary Pharmacology & Therapeutics.2025; 62(3): 244. CrossRef
Metabolic Impact of Alcohol Consumption in MASLD: Understanding MetALD and Beyond Eva Juárez-Hernández, Montserrat Berrospe-Alfaro, Misael Uribe, Iván López-Mendez Journal of Clinical and Experimental Hepatology.2025; 15(6): 103114. CrossRef
Current burden of MASLD, MetALD, and hepatic fibrosis among US adults with prediabetes and diabetes, 2017–2023 Donghee Kim, Rohit Loomba, Aijaz Ahmed Clinical and Molecular Hepatology.2025; 31(3): e235. CrossRef
Predicting the risk of lean non-alcoholic fatty liver disease based on interpretable machine models in a Chinese T2DM population Shixue Bao, Qiankai Jin, Tieqiao Wang, Yushan Mao, Guoqing Huang Frontiers in Endocrinology.2025;[Epub] CrossRef
Effect of varenicline on major adverse liver outcomes in alcohol‐associated liver disease: An exploratory analysis Pojsakorn Danpanichkul, Yanfang Pang, Donghee Kim, Thanathip Suenghataiphorn, Donghyun Ko, Andrew F. Ibrahim, Vitchapong Prasitsumrit, Kwanjit Duangsonk, Mazen Noureddin, Karn Wijarnpreecha, Suthat Liangpunsakul Alcohol, Clinical and Experimental Research.2025; 49(11): 2451. CrossRef
Paradoxical association between steatotic liver disease and favorable hepatic outcomes in HCV patients with SVRs Ming-Ling Chang, Jur-Shan Cheng, Jennifer Tai, Wei-Ting Chen, Sien-Sing Yang, Cheng-Hsun Chiu, Rong-Nan Chien, Chia-Lin Hsu, Shang-Jung Wu, Cathy SJ Fann Hepatology International.2025; 19(6): 1347. CrossRef
Extrahepatic manifestation of metabolic dysfunction-associated steatotic liver disease Anoushka Shenoy, Aijaz Ahmed, Donghee Kim Metabolism and Target Organ Damage.2025;[Epub] CrossRef
Obesity-Driven Metabolic Disorders: The Interplay of Inflammation and Mitochondrial Dysfunction Wooyoung Choi, Gun Ha Woo, Tae-Hwan Kwon, Jae-Han Jeon International Journal of Molecular Sciences.2025; 26(19): 9715. CrossRef
Metabolic dysfunction-associated steatotic liver disease: Prevalence and progression in lean patients Gerard Stupecki, Emilia Kowalczyk, Agnieszka Ciba-Stemplewska, Magdalena Dolecka-Ślusarczyk, Iwona Gorczyca-Głowacka Polish Annals of Medicine.2025; : 1. CrossRef
Increasing Prevalence of Steatotic Liver Disease in a Japanese Health Checkup Population, 2004–2022 Yuki Nakahata, Takao Miwa, Akihiro Obora, Takao Kojima, Nobuaki Yagi, Masahito Shimizu Liver International.2025;[Epub] CrossRef
The global landscape of lean metabolic dysfunction-associated steatotic liver disease: insight from Asia and the West Hery Djagat Purnomo, Randy Adiwinata, Cecilia Oktaria Permatadewi, Hesti Triwahyu Hutami, Didik Indiarso Frontiers in Gastroenterology.2025;[Epub] CrossRef
Role of ChREBP–PPARα–FGF21 Axis in Metabolic Dysfunction of MASLD Karina Mireya Palacios Girón, Zamira Helena Hernandez Nazara, Montserrat Maldonado-González, Erika Martínez-López, Martha P. Sánchez Muñoz, Carlos Alfredo Bautista López, Ma. Soledad Aldana Aguiñaga, Jose Alfredo Dominguez-Rosales, Belinda Vargas-Guerrero International Journal of Molecular Sciences.2025; 26(23): 11425. CrossRef
Implication of the Androgen Receptor in Muscle–Liver Crosstalk: An Overlooked Mechanistic Link in Lean-MASLD Eleni Myrto Trifylli, Christiana Charalambous, Nikolaos Spiliotopoulos, Nikolaos Papadopoulos, Anastasia Oikonomou, Spilios Manolakopoulos, Melanie Deutsch Livers.2025; 5(4): 65. CrossRef
Intestinal NLRP3 Deficiency Exacerbates MASLD in Male Mice via Reduced Butyrate Production Li Chen, Jing Li, Hao Yu Jia, Chun Liu, Shan Shan Li, Feng Shang Zhu, Chang Qing Yang Journal of Digestive Diseases.2025; 26(11-12): 544. CrossRef
Poor Sensitivity of the Fatty Liver Index Among Lean Individuals Mohammed Rifat Shaik, Yaron Rotman American Journal of Gastroenterology.2025;[Epub] CrossRef
PNPLA3 as a driver of steatotic liver disease: navigating from pathobiology to the clinics via epidemiology Ralf Weiskirchen, Amedeo Lonardo Journal of Translational Genetics and Genomics.2024; 8(4): 355. CrossRef
First
Prev
